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CONCLUSIONS:
 
 Despite the higher acquisition cost,
thromboprophylaxis with dalteparin is cost-efficacious ver-
sus warfarin in preventing DVT after THR.
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A COST COMPARISON STUDY OF AMLODIPINE 
AND ENALAPRIL AS TREATMENT FOR 
HYPERTENSION IN THE UNITED STATES
Doyle J, Arikian S, Casciano J, Amsel A, Casciano R
The Analytica Group, New York, NY, USA
OBJECTIVES: To compare the cost-effectiveness for treat-
ment of mild and moderate hypertension using either am-
lodipine or enalapril in the United States. The study is
based on data from a randomized controlled clinical trial,
conducted with 461 patients.
METHODS: We used the raw data from a one-year,
double blind clinical trial of amlodipine versus enalapril
to quantify the treatment dosages associated with each
patient group. The amlodipine group consisted of 231
patients, and the enalapril group included 230 patients.
Within the clinical trial, there were no between group sig-
nificant differences for age, gender, concomitant medica-
tions and current illness at randomization. Mean dosages
of amlodipine and enalapril, as well as the frequency and
dosage of diuretic use, were calculated between groups
based on age, gender and study phase, and were used to
estimate the cost of treatment. Efficacy and adverse event
rates were also calculated for each group to compare the
outcomes of the therapy.
RESULTS: Amlodipine ($551.62 per patient annual drug
treatment cost) was less expensive in treating the hyper-
tensive patients within the study as compared to enalapril
($663.48 per patient annual drug treatment cost). Fur-
thermore, a drug price sensitivity test found that with as
much as a 17% reduction in the cost of enalapril, amlo-
dipine would remain a lower or equivalent treatment in
terms of cost. The mean final visit dose amounts of drug
per patient were 7.2 mg/day for amlodipine, and 28 mg/
day enalapril. The total reduction in sitting DBP was
16.9 mmHg with amlodipine and 16.2 mmHg with enal-
april. However, significantly (p  0.05) more patients in
the enalapril group (n  46, 20%) required the use of a
diuretic (HCTZ) to attain control of DBP than in the am-
lodipine group (n  27, 11.7%). Finally, there were no
significant differences (p  0.05) in adverse events be-
tween groups (amlodipine  21.2%; enalapril  17.4%).
Yet, the type of adverse event differed by drug where a
significant effect (p  0.001) of amlodipine and edema
(15.2%) was found, and a significant effect (p  0.001)
for enalapril and cough (7.4%) was found.
CONCLUSION: This study suggests that amlodipine is a
less costly therapy compared to enalapril, and hence a
potentially more cost-effective treatment for mild and
moderate hypertension.
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THE COST OF HYPERTENSION AND ITS 
CORRELATES IN EMILIA ROMAGNA REGION 
(ITALY): RESULTS FROM THE GREAT STUDY
Ambrosioni E
 
1
 
, Belisari A
 
2
 
, Bustacchini S
 
3
 
, Costa FV
 
1
 
, 
Greco S
 
2
 
, Ruffo P
 
3
 
, Mantovani LG
 
2
 
 and the GREAT (GRoup 
on Economic Assessment of hyperTension) investigators
 
1
 
Clinica Medica III, Policlinico S. Orsola, Universita di Bologna, 
Bologna, Italy; 
 
2
 
Centro di Farmacoeconomia, Instituto di 
Scienze Farmacologiche, Universita di Milano, Milan, Italy; 
 
3
 
Pfizer Italiana, Rome, Italy
 
OBJECTIVE:
 
 Evaluation of the economic impact of hy-
pertension and its correlates.
 
METHODS:
 
 Twenty-seven GPs and 9 specialist centers
participated in this longitudinal study. Information on
lifestyle, SBP, DBP, comorbidities, diagnostic and lab ex-
ams, hospitalizations, physician’s visits, drug and medical
therapies was collected. We report on healthcare costs
(hospitalizations excluded), quantified in the perspective
of the Italian National Health Service (NHS), by means
of tariffs expressed in Italian Lire 1998, and referred to a
three-month period. We used multivariate linear regres-
sion to investigate the association between healthcare
costs, drug cost (or proper transformations) and the level
of SBP and DBP. P  0.05 were considered statistically
significant.
RESULTS: 416 patients were assessed, 210 women (mean
age 63  15) and 206 men (61  12). The mean levels of
SBP and DBP were 149  11 and 90  9 mmHg for men
and 149  15 and 88  9 mmHg for women. The total
three months cost of hypertension care was Lit 294.221
for men and Lit 253.938 for women (NS, Mann Whitney
U test). Drugs represented the largest part of costs (58%),
possibly due to the short time span. We found that new
patients tend to be less costly (P  0.006). Patients en-
rolled by specialists centers (P  0.001); patients with co-
morbidities (P  0.001); smokers (P  0.002) and previ-
ously hospitalized patients were more costly (P  0.001).
No influence of age and sex was detected. The health care
cost of hypertension was associated with the level of SBP
(P  0.007) and DBP (P  0.001). The cost of drug ther-
apy was significantly higher in patients with higher SBP
and DBP levels (P  0.001 and P  0.005 respectively).
DISCUSSION: Hypertension is a quite costly disease.
Healthcare costs of hypertension and the costs of anti-
hypertensive drug therapy are associated with the level
both of SBP and DBP. Interventions effective in controlling
SBP and DBP are likely to affect costs.
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HEALTH SERVICE (NHS) OF BIOLOGICAL AND 
MECHANICAL HEART VALVE REPLACEMENT IN 
YOUNGER VERSUS OLDER PATIENTS
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BACKGROUND:
 
 Selection of biological versus mechani-
cal heart valve replacement entails tradeoffs in the risk and
expected cost of post-operative bleeding, embolic events
and reoperation. Additionally, the risk of these events var-
ies by age at implant.
OBJECTIVE: To identify the direct medical costs to the
NHS of biological and mechanical valve replacement in
younger versus older patients.
METHODS: A Markov decision-analytic model was con-
structed to identify the cumulative lifetime costs of valve
replacement and related events in a simulated cohort of
10,000 patients followed from valve implantation until
death. Events included bleeding, embolism, endocarditis,
structural valve deterioration, reoperation and death. Event
rates were modeled using linear, and non-linear statistical
hazard functions based on clinical series reported in the
literature. Medical resource use related to events was es-
timated based on clinical expert opinion. Costs were as-
signed to each event using standard lists of NHS costs.
RESULTS: For aortic valve replacement, the expected life-
time costs were £6,812 (biological) and £8,873 (mechani-
cal) for persons aged 60, versus £6,281 (biological) and
£8,137 (mechanical) for persons aged 70 at implant, re-
spectively. In the mitral position, costs were £6,968 (biolog-
ical) and £8,760 (mechanical) versus £6,299 (biological)
and £7,989 (mechanical) in persons aged 60 versus 70 at
implant respectively. Results were most sensitive to bleed-
ing, embolic and reoperation event rates, but less sensitive
to the cost per event.
CONCLUSION: The expected lifetime cost of biologic
valve replacement was lower than mechanical valve re-
placement for both age groups and valve positions. This
suggests the economic impact of anticoagulation therapy,
bleeding and embolic events, which occur at higher rates in
the mechanical valve, is greater than the economic impact
of structural valve deterioration leading to reoperation,
which is greater in the biological valve.
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COST-EFFECTIVENESS OF STATINS: MOVING 
BEYOND THE PRIMARY AND SECONDARY 
PREVENTION DISTINCTION
 
Caro J, for the CORE Study Group
Caro Research Boston, MA, USA
BACKGROUND: Economic analyses of cardiovascular dis-
ease (CVD) prevention with statins have generated contro-
versy on the most efficient allocation of health care funds:
primary prevention, secondary or both? Previous analyses
have focused on one setting or the other. Comparing these
two oversimplifies the task of allocating health care re-
sources and may lead to unjustified decisions concerning
“appropriate” statin use. Instead, an integrated view across
the continuum of risk is required.
METHODS: An economic model of CVD prevention with
pravastatin—Continuum of Risk Evaluation (CORE)—
based on West of Scotland Coronary Prevention Study (pri-
mary prevention) and Cholesterol and Recurrent Events
(secondary prevention) study data is detailed. The model
simulates 10,000 individuals at various stages of CVD
(prior manifestation of CVD through multiple events). All
events are tallied in monthly cycles with costs and life ex-
pectancy implications applied appropriately.
ANALYSES: Analyses were completed for various popula-
tions and treatment strategies to help determine the most
cost-effective scenarios. For the purpose of these analyses,
populations were described in terms of the proportion of
individuals at various disease stages at the start of follow-
up. Treatment strategies were defined on the basis of the
risk cut-off at which treatment is initiated for individuals
without pre-existing disease. Analyses were conducted fol-
lowing the NCEP and Canadian treatment guidelines.
CONCLUSION: An integrated approach to prevention of
CVD is an area that has not been explored in term of its
economic impact. CORE permits realistic analysis of pol-
icy decisions which involve the entire continuum of risk
rather then isolated consideration of specific, but arbi-
trary, “stages” of disease.
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AMLODIPINE REDUCES HOSPITALIZATION 
ASSOCIATED WITH TREATMENT OF 
CARDIOVASCULAR DISEASES IN PATIENTS 
WITH CLINICAL CORONARY ARTERY DISEASE
Chen G, Byington R, Moran M
 
Department of Public Health Sciences and Internal Medicine, 
Wake Forest University School of Medicine, Winston-Salem, 
NC, USA
OBJECTIVE: To examine whether amlodipine can reduce
hospitalization associated with treatment of cardiovascu-
lar disease (CVD) in patients with angiographic evidence
of coronary artery disease. Amlodipine is a long acting cal-
cium channel antagonist that has been proven to be effec-
tive in treating cardiovascular diseases.
METHOD: We used clinical data derived from the Pro-
spective Randomized Evaluation of Vascular Effects of
Norvasc Trial (PREVENT). PREVENT was a 3-year, ran-
domized, masked, placebo-controlled, multicenter, clinical
trial originally designed to test the antiatherogenic effect of
the calcium channel blocker amlodipine in 825 patients
with coronary artery disease (417 patients for amlodipine
and 408 patients for placebo). The outcome measures were
clinical CVD events associated with hospital care which in-
cluded congestive heart failure (CHF), myocardial infarc-
tion (MI), stroke, angina, coronary artery bypass graft
(CABG), percutaneous coronary angioplasty (PTCA), stents,
athrectomy, valve replacement, and catheterization.
RESULTS: Overall, the net number of hospitalization asso-
ciated with CVD averted was 27.9 per 100 patients
(38.51% reduction) in the amlodipine patient group over
three years of the study. Comparing with the placebo group,
the treatment group had fewer hospitalizations related to
PTCA (11.75 per 100 patients, 52.69% reduction),
CABG (3.03, 42.62% reduction), stent (2.02, 41.22%
reduction), angina (9.27, 31.52% reduction), and CHF
